Roman Butler Fullerton & CO Krystal Biotech, Inc. Transaction History
Roman Butler Fullerton & CO
- $261 Million
- Q1 2025
A detailed history of Roman Butler Fullerton & CO transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Roman Butler Fullerton & CO holds 3,867 shares of KRYS stock, worth $511,565. This represents 0.27% of its overall portfolio holdings.
Number of Shares
3,867Holding current value
$511,565% of portfolio
0.27%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
328Shares Held
24.3MCall Options Held
299KPut Options Held
97.6K-
Black Rock Inc. New York, NY3.95MShares$522 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.83MShares$374 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.73MShares$361 Million7.97% of portfolio
-
State Street Corp Boston, MA1.23MShares$162 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA954KShares$126 Million0.03% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.4B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...